Stocksigma LogoStocksigma Logo

Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API

Shivalik Rasayan Limited has successfully filed a Drug Master File (DMF) with the USFDA for Avapritinib API, with the Complete Assessment already

Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API

Shivalik Rasayan Ltd 路 Others (Uncategorized) 路 03 Nov 2026, 7:25 pm

Shivalik Rasayan Files USFDA Drug Master File for Avapritinib API Shivalik Rasayan Limited has successfully filed a Drug Master File (DMF) with the USFDA for Avapritinib API, with the Complete Assessment already concluded. Avapritinib is indicated for the treatment of Gastrointestinal Stromal Tumors (GIST). The innovator product, marketed by Sanofi under the brand name Ayvakit, generated global revenues of USD 700 million during CY25. This regulatory milestone positions the company to target a commercially significant oncology market opportunity in the United States.

Original exchange filing (PDF)

More announcements from Shivalik Rasayan Ltd

All Shivalik Rasayan Ltd announcements